Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY5830966 in Myelofibrosis and Polycythemia Vera
NCT06343805Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2024
- Primary completion
- Jun 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 1, open-label trial of LY5830966 in myelofibrosis (MF) and polycythemia vera (PV) (10 cohorts), sponsored by Eli Lilly and Company. Primary endpoints: Treatment-Emergent Adverse Events at 1 year, Dose Limiting Toxicities at 1 year and 1 more. Started Oct 2024; status: recruiting.
02
Drugs
LY5830966
03
Conditions
myelofibrosis (MF)polycythemia vera (PV)
Beyond the preview
Go deeper on NCT06343805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06343805.